<div id="readability-page-1"><p>H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Arvinas Holding Company today and set a price target of $18.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Andrew Fein has given his Buy rating due to a combination of factors that highlight both near‑term execution and long‑term pipeline value. He views the VEPPANU licensing deal with Rigel as strategically attractive, since Rigel’s existing oncology infrastructure can support a rapid, efficient launch following early approval, while global rights with future sublicensing preserve additional upside.</p> <p>Fein also emphasizes that the temporary U.S. clinical hold on ARV‑102 in PSP appears procedural rather than safety‑related, with EU development progressing and offering a potentially swift path to proof‑of‑concept. In parallel, he sees meaningful optionality in the KRAS and BCL6 programs, where a more selective KRAS G12D degrader, favorable immunologic profile, and emerging activity in AITL collectively differentiate Arvinas’s platform, supporting a maintained $18 price target and Buy rating.</p> <p>In another report released today, Barclays also assigned a Buy rating to the stock with a $20.00 price target.</p> </div>

ARVN

RIGL

<p>H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Arvinas Holding Company, maintaining a price target of $18. The rating is based on the company's near-term execution and long-term pipeline value, particularly highlighting the VEPPANU licensing deal with Rigel. Fein noted that the U.S. clinical hold on ARV-102 appears procedural, with EU development progressing. He also sees potential in the KRAS and BCL6 programs. Barclays also assigned a Buy rating with a $20 price target.</p>

Tip Ranks

Arvinas

Rigel Pharma

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Barclays

Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target